Novartis was not in breach of code for "inventing" disease
نویسندگان
چکیده
منابع مشابه
study of cohesive devices in the textbook of english for the students of apsychology by rastegarpour
this study investigates the cohesive devices used in the textbook of english for the students of psychology. the research questions and hypotheses in the present study are based on what frequency and distribution of grammatical and lexical cohesive devices are. then, to answer the questions all grammatical and lexical cohesive devices in reading comprehension passages from 6 units of 21units th...
Lumiracoxib (Novartis).
Lumiracoxib, an inhibitor of cyclooxygenase 2 (COX-2), is under development by Novartis for the potential treatment of osteoarthritis, rheumatoid arthritis and pain. By late December 2000, phase III trials had been initiated and were ongoing in December 2001.
متن کاملHow to Steal Code -or- Inventing The Wheel Only Once
Much is said about ‘‘standing on other people’s shoulders, not their toes’’, but in fact the wheel is re-invented every day in the Unix/C community. Worse, often it is reinvented badly, with bumps, corners, and cracks. There are ways of avoiding this: some of them bad, some of them good, most of them under-appreciated and under-used.
متن کاملcomparsion of lower exteremity disorderies between wrestling atheletes of menisci, acl injuries and not injuries speacment in kermanshah
پیش گیری از آسیب های ورزشی مهمترین موضوع در برخورد با آسیب های ورزشی است. برای پیش گیری از آسیب های ورزشی شناسایی عوامل و ریسک فاکتورهای مستعد کننده آسیب از اهمیت ویژه ای برخوردار است. هدف از انجام این تحقیق شناسایی ریسک فاکتورهای آسیب در بین کشتی گیران نخبه استان کرمانشاه می باشد. بدین منظور60 نفر کشتی گیر در سه گروه شامل: آسیب دیده منیسک، رباط صلیبی قدامی و افراد غیر آسیب دیده در گروههای20 نف...
15 صفحه اولFingolimod. Mitsubishi Pharma/Novartis.
Mitsubishi Pharma Corp and Novartis AG are developing fingolimod, an orally active immunosuppressant affecting lymphocyte re-circulation, for the potential prevention of transplant rejection and the treatment of autoimmune diseases, including multiple sclerosis. Fingolimodis a synthetic sphingosine analog that becomes phosphorylated in vivo and acts as a sphingosine-1-phosphate receptor agonist.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 2003
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.326.7385.396